Light Horse Therapeutics is a San Diego-based developer of small-molecule therapeutics. The company has built a proprietary platform that uncovers novel functional sites in disease-critical targets by integrating approaches and a precision genetic editing–based platform that interrogates proteins in their native environment. Its function-first discovery approach identifies novel functional domains before screening for chemistry, reversing traditional screening-first methodologies. The technology is intended to improve discovery of clinical candidates by revealing previously hidden functional domains. Light Horse says it will use proceeds from its recent financing to expand operations and advance its development efforts. The company is led by CEO Markus Renschler and its team includes CSO Laure Escoubet and scientific co-founders Brian Liau, Ben Cravatt and Nathanael Gray.

Total raised

$62M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025